Randomized Trial of Fluticasone in Bronchial Premalignancy

Overview

The purpose of this study is to assess the efficacy of fluticasone on the development of lung cancer in smokers

Full Title of Study: “The Influence of Fluticasone Inhalation on Intermediate Markers of Carcinogenesis in the Bronchial Epithelium of a High Risk Population : A Double Blind Placebo-Controlled Randomised Phase II Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Prevention
    • Masking: Double

Detailed Description

Bronchial epithelium exposed to cigarette smoke undergoes a series of histological changes that may ultimately lead to invasive cancer. In rats exposed to cigarette smoke inhaled corticosteroids reduce the number of lung tumors. The purpose of this study is to assess the efficacy of fluticasone on premalignant lesions in volunteers with a smoking history of >10 pack-years and patients cured of head and neck cancer or lung cancer. Participants are screened for premalignant lesions by bronchoscopy and if these are present randomised to receive a powder inhalation device containing either fluticasone 500 μg or a placebo. After 6 months, biopsies are taken from the same locations. Efficacy of treatment is assessed by reversal of metaplasia/dysplasia; secondary end-points are reversal of increased p53 immunoreactivity and hTERT expression.

Interventions

  • Drug: Fluticasone propionate

Clinical Trial Outcome Measures

Primary Measures

  • Reversal of histological abnormality bronchial biopsies at 6 months

Secondary Measures

  • Reversal of suprabasal p53 staining at 6 months
  • Reversal of elevated hTERT mRNA levels at 6 months
  • Reversal of increased KI-67 at 6 months

Participating in This Clinical Trial

Inclusion Criteria

  • signed informed consent – age over 18 – metaplasia index > 15% – over 25 pack years smoking history or history of lung- or head&neck cancer – male/female of non-childbearing potential or using approved contraception Exclusion Criteria:

  • use of inhaled/systemic corticosteroid drugs in the preceding 12 months – contraindications for bronchoscopy/use of fluticasone – major illness – Baseline FEV1<1000ml – Previous participation in clinical study – nodules > 1cm on CT

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Amsterdam UMC, location VUmc
  • Collaborator
    • GlaxoSmithKline
  • Overall Official(s)
    • Egbert F Smit, MD PHD, Principal Investigator, Amsterdam UMC, location VUmc

References

Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Galbraith AR, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis. 2000 Feb;21(2):179-82. doi: 10.1093/carcin/21.2.179.

Breuer RH, Snijders PJ, Sutedja TG, v d Linden H, Risse EK, Meijer CJ, Postmus PE, Smit EF. Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancer. Lung Cancer. 2003 May;40(2):165-72. doi: 10.1016/s0169-5002(03)00029-1.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.